GGrantIndex
← Leaderboards

Bin Wang

University Of Pittsburgh At Pittsburgh

$5,294,391
Attributed
$5,294,391
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY201324
$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$5,294,391 · 6

By mechanism

R01$4,459,519 · 3
R03$462,500 · 2
R21$372,372 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Pathway Interactions

Research focus

Pathway InteractionsSignal TransductionParathyroid Hormone ReceptorSignal PathwayResponseMediatingIn VivoCyclic AmpDesignBaseReceptorPreventBone ResorptionGtp-Binding Protein Alpha Subunits, GsPth GeneOsteogenesisOsteoblastsAnabolic AgentsBoneReceptor SignalingOsteoporosisCellsOsteoclastsBeta Catenin

Grant awards (21)

Targeting the PTH1R Signaling Pathway for Osteoarthritis Therapy by a Novel Disruptor Peptide$332,904
R01 · FY2024 · AR · contact PI
Targeting the ubiquitin-proteasome pathway to reverse catabolic action of PTH in bone$320,046
R01 · FY2024 · AG · contact PI
Targeting the PTH1R Signaling Pathway for Osteoarthritis Therapy by a Novel Disruptor Peptide$343,200
R01 · FY2023 · AR · contact PI
Targeting the ubiquitin-proteasome pathway to reverse catabolic action of PTH in bone$320,046
R01 · FY2023 · AG · contact PI
Targeting the PTH1R Signaling Pathway for Osteoarthritis Therapy by a Novel Disruptor Peptide$339,768
R01 · FY2022 · AR · contact PI
Targeting the ubiquitin-proteasome pathway to reverse catabolic action of PTH in bone$320,046
R01 · FY2022 · AG · contact PI
Novel Molecular and Cellular Mechanisms for Osteoanabolic Action of Parathyroid Hormone$380,579
R01 · FY2021 · DK · contact PI
Targeting the PTH1R Signaling Pathway for Osteoarthritis Therapy by a Novel Disruptor Peptide$332,904
R01 · FY2021 · AR · contact PI
Targeting the ubiquitin-proteasome pathway to reverse catabolic action of PTH in bone$324,169
R01 · FY2021 · AG · contact PI
Biasing OGR1 signaling to optimizing PTH therapeutic effect$166,452
R21 · FY2021 · AR · contact PI
Novel Molecular and Cellular Mechanisms for Osteoanabolic Action of Parathyroid Hormone$385,630
R01 · FY2020 · DK · contact PI
Targeting the PTH1R Signaling Pathway for Osteoarthritis Therapy by a Novel Disruptor Peptide$343,200
R01 · FY2020 · AR · contact PI
Targeting the ubiquitin-proteasome pathway to reverse catabolic action of PTH in bone$327,027
R01 · FY2020 · AG · contact PI
Biasing OGR1 signaling to optimizing PTH therapeutic effect$205,920
R21 · FY2020 · AR · contact PI
Novel Molecular and Cellular Mechanisms for Osteoanabolic Action of Parathyroid Hormone$390,000
R01 · FY2019 · DK · contact PI
Novel Mechanism of PTH Effects on Bone Metabolism$77,500
R03 · FY2015 · AR · contact PI
Novel Regulation of PTH Receptor Functions in Bone$77,500
R03 · FY2015 · AR · contact PI
Novel Regulation of PTH Receptor Functions in Bone$77,500
R03 · FY2014 · AR · contact PI
Novel Mechanism of PTH Effects on Bone Metabolism$77,500
R03 · FY2014 · AR · contact PI
Novel Mechanism of PTH Effects on Bone Metabolism$76,250
R03 · FY2013 · AR · contact PI
Novel Regulation of PTH Receptor Functions in Bone$76,250
R03 · FY2013 · AR · contact PI